#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

Abemaciclib for HR+/HER2- advanced or metastatic breast cancerПодробнее

Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancerПодробнее

Expert commentary: MONARCH 3 trial | Rodrigo DienstmannПодробнее

MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancerПодробнее

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim dataПодробнее

Metastatic breast cancer at ESMO 2022: TROPiCS02, MONARCH 3 and SYNERGYПодробнее

Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancerПодробнее

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancerПодробнее

#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02Подробнее

postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapyПодробнее

#ESMO22 Highlights on pembrolizumab with CRT in locally advanced HNSCC: The KEYNOTE-412 studyПодробнее

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancerПодробнее

Highlights from ESMO Breast Cancer 2022Подробнее

Breast cancer trials of interest at ESMO 2022Подробнее

ESMO 2022: Breast cancer highlightsПодробнее

Breast cancer at ESMO 2023: ADCs and MONARCH 3Подробнее

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801Подробнее